Literature DB >> 31456008

[Intensive care aspects of autoimmune encephalitis].

A Günther1, J Schubert2, O W Witte2, D Brämer2.   

Abstract

Autoimmune encephalitis is a rare, rapidly progressive and potentially severe inflammatory brain disease, usually mediated by autoantibodies. Frequently, the affected patients go through various phases of the disease with prodromi, neuropsychological abnormalities, severe neurological and autonomic disorders and usually long reconvalescence. In up to 85% of patients intensive care treatment is necessary, especially in the group of anti-NMDA receptor encephalitis (NMDA-RE). Typical problems during ICU stay include: severe qualitative and quantitative disturbances of consciousness, autonomic dysfunction, epileptic seizures/epileptic status, treatment-refractory movement disorders, as well as ventilation and weaning problems requiring tracheotomy. But also ethical conflicts and general ICU complications such as sepsis, the need for resuscitation, as well as surgical and psychiatric complications occur. The outcome is highly heterogeneous with a range from complete recovery to the most severe, persistent disorders of consciousness with extensive care and death. Mortality data also vary at between 12% and 40%. Patients requiring mechanical ventilation and tracheostomy and with sepsis and autonomic dysfunction are prone to worse outcomes. A large part of the presented data refers to a recently published multicenter, Germany-wide retrospective cohort study and brought into the context of existing literature.

Entities:  

Keywords:  Critical care outcomes; Ethical issues; Mechanical ventilation; N-Methyl-D-Asparatate; Tracheostomy

Mesh:

Substances:

Year:  2019        PMID: 31456008     DOI: 10.1007/s00063-019-0604-5

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  24 in total

1.  Long-term cognitive impairment and functional disability among survivors of severe sepsis.

Authors:  Theodore J Iwashyna; E Wesley Ely; Dylan M Smith; Kenneth M Langa
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

2.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

3.  Anti-N-Methyl-d-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care.

Authors:  Etienne de Montmollin; Sophie Demeret; Noëlle Brulé; Marie Conrad; Frédéric Dailler; Nicolas Lerolle; Jean-Christophe Navellou; Carole Schwebel; Mikaël Alves; Martin Cour; Nicolas Engrand; Jean-Marie Tonnelier; Eric Maury; Stéphane Ruckly; Géraldine Picard; Véronique Rogemond; Éric Magalhaes; Tarek Sharshar; Jean-François Timsit; Jérôme Honnorat; Romain Sonneville
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

4.  Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: A systematic review of cases.

Authors:  Nicola Warren; Vanessa Grote; Cullen O'Gorman; Dan Siskind
Journal:  Brain Stimul       Date:  2018-12-04       Impact factor: 8.955

5.  Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.

Authors:  Eoin P Flanagan; Shannon R Hinson; Vanda A Lennon; Boyan Fang; Allen J Aksamit; P Pearse Morris; Eati Basal; Josephe A Honorat; Nora B Alfugham; Jenny J Linnoila; Brian G Weinshenker; Sean J Pittock; Andrew McKeon
Journal:  Ann Neurol       Date:  2017-02       Impact factor: 10.422

6.  [Therapeutic apheresis for autoimmune encephalitis: a nationwide data collection].

Authors:  S Ehrlich; C M Fassbender; C Blaes; C Finke; A Günther; L Harms; F Hoffmann; K Jahner; R Klingel; A Kraft; T Lempert; M Tesch; J Thomsen; H Topka; J Jochim; C Veauthier; W Köhler
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

7.  Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study.

Authors: 
Journal:  Intensive Care Med       Date:  2016-09-29       Impact factor: 17.440

Review 8.  Prognosticating autoimmune encephalitis: A systematic review.

Authors:  James Broadley; Udaya Seneviratne; Paul Beech; Katherine Buzzard; Helmut Butzkueven; Terence O'Brien; Mastura Monif
Journal:  J Autoimmun       Date:  2018-10-26       Impact factor: 7.094

9.  Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.

Authors:  Alexander Carvajal-González; M Isabel Leite; Patrick Waters; Mark Woodhall; Ester Coutinho; Bettina Balint; Bethan Lang; Philippa Pettingill; Aisling Carr; Una-Marie Sheerin; Rayomand Press; Raomand Press; Michael P Lunn; Ming Lim; Paul Maddison; H-M Meinck; Wim Vandenberghe; Angela Vincent
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

10.  Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment.

Authors:  Julia Schubert; Dirk Brämer; Hagen B Huttner; Stefan T Gerner; Hannah Fuhrer; Nico Melzer; Andre Dik; Harald Prüss; Lam-Than Ly; Kornelius Fuchs; Frank Leypoldt; Gunnar Nissen; Ingo Schirotzek; Christian Dohmen; Julian Bösel; Jan Lewerenz; Franziska Thaler; Andrea Kraft; Aleksandra Juranek; Marius Ringelstein; Kurt-Wolfram Sühs; Christian Urbanek; André Scherag; Christian Geis; Otto W Witte; Albrecht Günther
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-10-30
View more
  1 in total

Review 1.  Dysfunction of the Autonomic Nervous System and its Role in the Pathogenesis of Septic Critical Illness (Review).

Authors:  Y Y Kiryachkov; S A Bosenko; B G Muslimov; M V Petrova
Journal:  Sovrem Tekhnologii Med       Date:  2020-08-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.